Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
78 hedge funds and large institutions have $90.2M invested in Forte Biosciences in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 18 closing their positions.
418% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $346K
138% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 13
29% more capital invested
Capital invested by funds: $70.1M → $90.2M (+$20.1M)
0% less ownership
Funds ownership: 0.1% → 0.1% (-0%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
3% less funds holding
Funds holding: 80 → 78 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.64M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.24M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.12M |
| 5 |
Morgan Stanley
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$4.55M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.95M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1M |
| 4 |
HP
Hound Partners
New York
|
-$871K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$699K |
FBRX Hedge Fund Activity: Q1 2019 in Review
78 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q1 2019, worth a combined $90.2M — up 29% from $70.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of FBRX and 17 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 31 added.
The largest buyer was BlackRock, adding an estimated $1.64M. The largest seller was Citigroup, cutting an estimated $4.55M.
- 78 institutional investors held Forte Biosciences (FBRX) as of Q1 2019, down from 80 in Q4 2018.
- Funds reported $90.2M of Forte Biosciences stock for Q1 2019, up 29% quarter-over-quarter.
- 17 funds opened new Forte Biosciences positions in Q1 2019 and 18 closed out, a net change of -1 holder.
- The largest Forte Biosciences buyer in Q1 2019 was BlackRock, an estimated $1.64M added.
- The largest Forte Biosciences seller in Q1 2019 was Citigroup, an estimated $4.55M sold.
Based on aggregated 13F filings for Q1 2019.